The Korea National Enterprise for Clinical Trials (KoNECT) will co-host the "Global Investment Attraction Strategy Seminar for Korean Biotech Firms" with Harvest integrated Research Organization (HiRO) on March 28.

The seminar will be held for the first time to provide networking with global investors and global clinical development consulting to help domestic biotech companies that are facing difficulties, such as the suspension of clinical trials due to the shrinking investment market in the biotech industry, continue their innovative R&D, KoNECT said Wednesday.

Global venture capitalists from the U.S., China, Hong Kong, and other countries will participate as panelists and consultants.

The seminar will provide various programs, including sharing strategies for successful global investment, one-on-one global investment matching consulting, one-on-one global clinical development matching consulting, and networking among participating organizations.

HiRO, a global contract research organization, will co-host the event and participate in global clinical development matching consulting.

"It is very difficult to develop new drugs as many domestic biotech companies have recently abandoned R&D or stopped clinical trials," KoNECT Chairperson Park In-seok said. "We hope that through this seminar, domestic biotech companies with sufficient capabilities will be able to explore global investment and commercialization strategies and continue innovative R&D."

Would-be participants can apply for the event by email and can download the application form from the notice board on the foundation's website (www.konect.or.kr).